Cargando…
Universal Germline Testing of Unselected Cancer Patients Detects Pathogenic Variants Missed by Standard Guidelines without Increasing Healthcare Costs
SIMPLE SUMMARY: Clinical genetic testing likely underestimates the frequency of pathogenic germline variants (PGVs) in a cancer patient population due to strict qualifications designated by practice guidelines. Accurate ascertainment of PGVs in cancer patients can be paramount to the treatment of he...
Autores principales: | Perkins, Adrienne T., Haslem, Derrick, Goldsberry, Jessica, Shortt, Katherine, Sittig, Laura, Raghunath, Sharanya, Giauque, Christopher, Snow, Shawnee, Fulde, Gail, Moulton, Bryce, Jones, David, Nadauld, Lincoln |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616044/ https://www.ncbi.nlm.nih.gov/pubmed/34830767 http://dx.doi.org/10.3390/cancers13225612 |
Ejemplares similares
-
An elevated neutrophil-to-lymphocyte ratio associates with weight loss and cachexia in cancer
por: Barker, Tyler, et al.
Publicado: (2020) -
Precision oncology in advanced cancer patients improves overall survival with lower weekly healthcare costs
por: Haslem, Derrick S., et al.
Publicado: (2018) -
Germline variants of ATG7 in familial cholangiocarcinoma alter autophagy and p62
por: Greer, Stephanie U., et al.
Publicado: (2022) -
Precision Oncology Strategy in Trastuzumab-Resistant Human Epidermal Growth Factor Receptor 2–Positive Colon Cancer: Case Report of Durable Response to Ado-Trastuzumab Emtansine
por: Haslem, Derrick S., et al.
Publicado: (2017) -
A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs
por: Haslem, Derrick S., et al.
Publicado: (2017)